On Tuesday, June 3, Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” rating.
The decision came after Genmab A/S shared new data on Rina-S in second-line and endometrial cancer treatments at the American Society of Clinical Oncology (ASCO) Annual Meeting.
A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.
The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year. Analysts at Leerink Partners see this as a good sign for Genmab A/S’s future prospects in treating endometrial cancer.
At the ASCO meeting, the company highlighted how Rina-S could address unmet needs in the treatment of endometrial cancer. Genmab A/S plans to move its clinical trials forward to explore the efficacy of Rina-S.
Genmab A/S is a Danish biotechnology company that focuses on developing antibody therapeutics for cancer and other serious diseases.
READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds.
